Parkinson's patients in Brazil turn to a movement practice known as capoeira to ease symptoms
That changed after she began attending a capoeira class in downtown Rio de Janeiro especially designed for people with the neurodegenerative illness.
Capoeira is a movement practice that originated within the large enslaved communities in Brazil, where nearly 5 million kidnapped Africans disembarked during the transatlantic slave trade that started in the 16th century.
It is considered both a martial art and a dance, combining ritual, exercise, spirituality and music.
'Capoeira gives me freedom to work on my body. What I can do. What I can't do. So I can have balance and a more comfortable life,' Teles de Freitas said during a recent class.
Practiced for centuries by Afro-Brazilians, it has since become popular around the world. UNESCO recognized the practice in 2014 as Intangible Cultural Heritage.
The project started in 2018 with physical therapist Rosimeire Peixoto, 60, who at that point had been attending capoeira classes herself for over a decade.
After working with many patients with Parkinson's, she said she became convinced that introducing them to capoeira may help alleviate some of their symptoms.
Parkinson's has a range of different symptoms, and along with difficulties in balancing, some common ones include slowness of movement, tremors and stooped posture. Patients can also experience anxiety, depression, sleeping disorders and nausea.
'I had the idea after reading an article that said alternating both hands when using a cell phone stimulates both hemispheres of the brain,' she said. 'And as a physiotherapist treating neurological patients, I was lacking exercises that would motivate them.'
Peixoto's project was dubbed 'Parkinson na ginga' — or 'Parkinson's in the swing' — a reference to the first fluid, rhythmic step that capoeira practitioners learn. She now holds classes twice a week in the Progress Foundry, a sprawling cultural center in downtown Rio next to a famed white 18th century aqueduct and surrounded by palm trees.
Capoeira helps improve balance, coordination and strength, with music loosening up tense bodies, Peixoto says.
'There is a lot happening in a capoeira circle. They feel the vibration, the energy, they pay attention to the music and to the partner to dodge blows' and to themselves, she said.
During a recent class, Peixoto walked among the students, placing a gentle hand on a back here and there to help with balance, patiently repeating demonstrations and offering words of encouragement.
Antônio de Azevedo, who was diagnosed with Parkinson's disease a few years ago, said he could hardly stand before. But since he started practicing capoeira, his stability returned.
'It's the best thing that's ever happened to me,' he said while he attended a capoeira class with around 10 other people, all with Parkinson's.
Peixoto tries to make the classes a fun and social event — she often suggests a group samba dance at the end of the class, and regularly brings a cake to share.
Teles de Freitas, the retired teacher, says that she loves the camaraderie among the class.
'We are there for one another,' she said. 'Feeling and conversing with friends gives strength.'
She remembers how when she got her diagnosis, she left the doctor's office crying, terrified of the future.
'Today I'm smiling,' she said. 'I'm managing to live. I'm managing to interact with other people. I'm managing to be happy.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
DNAKE Emerges as a Global Innovator in Brain-Computer Interface Technology
XIAMEN, China, July 18, 2025 /PRNewswire/ -- Brain-Computer Interface (BCI) technology is redefining human-machine interaction by establishing direct communication between the brain and external devices. This transformative innovation is driving profound societal impact across industries: revolutionizing neurological disease treatment (e.g., epilepsy, Parkinson's, and depression), enhancing educational outcomes through improved focus, and enabling seamless industrial human-robot collaboration. With aging populations and rising neurological disorders worldwide, BCI's healthcare applications are experiencing explosive demand. According to IMARC Group, the global BCI market reached $1.74 billion in 2022 and is projected to hit $3.3 billion by 2027. In this rapidly evolving field, DNAKE is establishing itself as a rising force through cutting-edge R&D and global vision. Technology Leadership & Standardization As a key driver of BCI advancement, DNAKE has forged strategic partnerships with elite research institutions like the CAS Key Laboratory of Brain Function and Diseases, Xiamen University's Brain Cognition & Intelligent Computing Lab, etc. These collaborations underscore its dual strengths: proprietary innovation and integration of top-tier academic resources. DNAKE holds pivotal roles in the BCI Industry Alliance and China Communications Standards Association, actively co-authoring technical standards such as "EEG-Based Attention Monitoring Systems: Technical Requirements and Testing Methods." This standardization expertise positions DNAKE to extend its influence into global markets, where consistent technical benchmarks are critical for adoption. Breakthrough Innovations DNAKE's BCI team recently published groundbreaking research in the Annals of the New York Academy of Sciences, solving a critical industry challenge: environmental adaptability. Their innovative "Human-AI Multi-agent Copilot" system merges EEG signal decoding with deep reinforcement learning AI, enabling devices to interpret user commands while autonomously responding to environmental changes—a leap from one-directional BCI systems to true interactive intelligence. In sleep health, Dr. Phang's team also developed a Multiscale Temporal Convolutional Neural Network (MTCNN) algorithm in the Journal of Neural Engineering that achieves 88.24% accuracy in sleep-stage classification—a 23% improvement over consumer-grade headbands (Miller et al., 2022). This approach sets new paradigms for EEG signal analysis. R&D Commitment DNAKE's 300+ member R&D team includes specialized BCI engineers, with 2024 R&D investment spiking to 11% of revenue. A dedicated $18 million BCI Technology Center will accelerate project commercialization. Strategic Vision Aligned with its "Innovation-Driven Transformation" strategy, DNAKE is pivoting toward digital health ecosystems while strengthening its smart community and hospital solutions. "In BCI, Chinese innovators compete on equal footing globally," notes DNAKE. "Through autonomous R&D and international collaboration, we're poised to shape BCI's future." About DNAKE DNAKE (Xiamen) Intelligent Technology Co., Ltd. is a global leader in smart intercom and home automation solutions. Since 2005, we've delivered innovative, high-quality products—including IP intercoms, cloud platforms, smart sensors, and wireless doorbells—to over 12.6 million households worldwide. Combining cutting-edge technology with customer-focused design, DNAKE provides reliable, scalable solutions for both residential and commercial needs. View original content: SOURCE DNAKE (Xiamen) Intelligent Technology Co., Ltd.
Yahoo
17 hours ago
- Yahoo
World Brain Day: brain health and an ageing population
World Brain Day, celebrated annually on 22 July, serves as a call to action for increased neurological health awareness and advocacy. In the context of a rapidly ageing global population, the burden of neurodegenerative diseases such as Alzheimer's and Parkinson's disease is rising, posing significant challenges to healthcare systems. These progressive disorders not only diminish quality of life, but also contribute substantially to disability and dependency among older adults. Apart from posing a public health concern, they pose personal issues affecting individuals and families, and contribute to long-term care needs among the elderly, both for professional and informal care. These diseases erode memory and independence, and often lead to emotional and physical hardship for patients and families. Cases of Alzheimer's disease and Parkinson's disease (PD) are increasing globally. Several factors are contributing to the increasing prevalence of Alzheimer's and PD. These included the ageing population and increased detection and diagnosis. GlobalData's Alzheimer's and PD epidemiology forecasts shed light on the future burden of these diseases. The latest report forecasts an increase in the diagnosed prevalent cases of Alzheimer's in the eight major markets (8MM: China, France, Germany, Italy, Japan, Spain, the UK and the US) from approximately 11 million in 2025 to more than 12.3 million in 2028. Diagnosed prevalent cases of PD are expected to increase from 2.7 million cases in 2025 to 3.1 million cases in 2033 in the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the US). Understanding the key risk factors and potential challenges of managing these diseases will help healthcare providers and patients recognise symptoms earlier, which could slow disease progression, understand individual risk factors, and coordinate care among different health professionals, such as neurologists, primary care providers and caregivers. With global life expectancy rising, the at-risk population for Alzheimer's and PD will grow. Awareness days can help educate people on professional and self-administered screening tools for signs of memory and cognitive impairment related to Alzheimer's, such as the Mini-Mental State Examination (MMSE) and Mini-Cog (administered by professionals), and the self-administered test called SAGE (the Self-Administered Gerocognitive Exam). In the case of PD, events such as World Brain Day can shed light on symptoms such as tremors, stiffness and slow movement. Awareness days draw attention to diseases. They advance global notice, understanding and diagnosis. By spotlighting brain health on an international stage, the campaign encourages collaboration among researchers, clinicians and policymakers to address gaps in access to care and treatment. This is important when we consider that Alzheimer's and PD are major challenges in an ageing world. "World Brain Day: brain health and an ageing population" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Los Angeles Times
a day ago
- Los Angeles Times
Robert Fried Says Niagen Bioscience Has the Key to Better Aging, and He Has the Science to Prove It
In a recent interview, Robert Fried, CEO of Niagen Bioscience, delves into the science of aging and the pivotal role of a molecule known as NAD (nicotinamide adenine dinucleotide). He explains how NAD is crucial for cellular energy and repair, and how its decline with age contributes to a slower recovery from injuries and the progression of age-related conditions. Fried clarifies a common misconception: NAD itself is not bioavailable when taken orally. Instead, he highlights the importance of a precursor molecule, nicotinamide riboside, which is readily absorbed by cells and converted into NAD. Niagen Bioscience's flagship product, Niagen, is a patented and extensively researched form of nicotinamide riboside. A significant concern for Fried is the lack of integrity in the broader dietary supplement market. He cites a study where less than 1% of competing NAD-boosting products met their label claims, with 40% containing none of the active ingredient. He contrasts this with Niagen Bioscience's commitment to rigorous scientific research, evidenced by 38 peer-reviewed human clinical studies and over 100 preclinical studies. Fried emphasizes that Niagen Bioscience is not just another supplement company. They are singularly focused on NAD and its potential therapeutic benefits. A major four-and-a-half-year study on Parkinson's disease, involving 400 participants, is nearing completion and is expected to provide further evidence of Niagen's potential to address serious age-related diseases. The company's mission, according to Fried, is to educate the public about the importance of NAD and to establish Niagen as the 'gold standard' in the NAD space. He stresses that Niagen is the only patented, legal, and trusted form of nicotinamide riboside, backed by unparalleled scientific research.